NCT04699903View on ClinicalTrials.gov

Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood

CompletedOBSERVATIONAL
Enrollment

201

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

January 29, 2021

Study Completion Date

April 9, 2021

Conditions
SARS-Cov-2, Covid19
Interventions
DIAGNOSTIC_TEST

POC SARS-Cov-2 IgG Antibody test

All patients will undergo a Point of care (POC) SARS-Cov-2 IgG Antibody test in fingerstick whole blood

Trial Locations (3)

33409

Comprehensive Clinical Research, West Palm Beach

60640

Great Lakes Clinical Trials (GLCT), Chicago

92324

Benchmark - SoCal, Colton

Sponsors

Lead Sponsor

Lumos Diagnostics
All Listed Sponsors
collaborator

Rapid Pathogen Screening

INDUSTRY

lead

Lumos Diagnostics

INDUSTRY

NCT04699903 - Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood | Biotech Hunter | Biotech Hunter